Flucofuron as a Promising Therapeutic Agent against Brain-Eating Amoeba.
ACS Infect Dis
; 10(6): 2063-2073, 2024 Jun 14.
Article
em En
| MEDLINE
| ID: mdl-38757533
ABSTRACT
Primary amoebic meningoencephalitis (PAM) is a rare and fulminant neurodegenerative disease caused by the free-living amoeba Naegleria fowleri. Currently, there is a lack of standardized protocols for therapeutic action. In response to the critical need for effective therapeutic agents, we explored the Global Health Priority Box, a collection of 240 compounds provided by the Medicines for Malaria Venture (MMV). From this pool, flucofuron emerged as a promising candidate, exhibiting high efficacy against trophozoites of both N. fowleri strains (ATCC 30808 IC50 2.58 ± 0.64 µM and ATCC 30215 IC50 2.47 ± 0.38 µM), being even active against the resistant cyst stage (IC50 0.88 ± 0.07 µM). Moreover, flucofuron induced diverse metabolic events that suggest the triggering of apoptotic cell death. This study highlights the potential of repurposing medications for treating challenging diseases, such as PAM.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Naegleria fowleri
Limite:
Humans
Idioma:
En
Revista:
ACS Infect Dis
/
ACS infect. dis
/
ACS infectious diseases
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Espanha